Inhibition of MEK/ERK1/2 and PKC by STP or UCN-01 can both contribute to their VA sensitisation effect in thoracic cancer cells, yet the relative contribution of each to this effect is not clear at present. Here, PRRT2 is linked to thoracic cancer.